GR3022302T3 - Method for determining the presence of diabetes associated antibodies or islet cell directed antibodies - Google Patents

Method for determining the presence of diabetes associated antibodies or islet cell directed antibodies

Info

Publication number
GR3022302T3
GR3022302T3 GR970400062T GR970400062T GR3022302T3 GR 3022302 T3 GR3022302 T3 GR 3022302T3 GR 970400062 T GR970400062 T GR 970400062T GR 970400062 T GR970400062 T GR 970400062T GR 3022302 T3 GR3022302 T3 GR 3022302T3
Authority
GR
Greece
Prior art keywords
antibodies
glucose
insulin
diabetes
gene
Prior art date
Application number
GR970400062T
Other languages
English (en)
Inventor
Christopher B Newgard
Roger H Unger
John H Johnson
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of GR3022302T3 publication Critical patent/GR3022302T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01001—Hexokinase (2.7.1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
GR970400062T 1991-06-03 1997-01-16 Method for determining the presence of diabetes associated antibodies or islet cell directed antibodies GR3022302T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71003891A 1991-06-03 1991-06-03
US07/819,326 US5427940A (en) 1991-06-03 1992-01-13 Engineered cells producing insulin in response to glucose
PCT/US1992/004737 WO1992021979A1 (en) 1991-06-03 1992-06-02 Methods and compositions relating to genetically engineered cells that produce insulin in response to glucose

Publications (1)

Publication Number Publication Date
GR3022302T3 true GR3022302T3 (en) 1997-04-30

Family

ID=27108362

Family Applications (1)

Application Number Title Priority Date Filing Date
GR970400062T GR3022302T3 (en) 1991-06-03 1997-01-16 Method for determining the presence of diabetes associated antibodies or islet cell directed antibodies

Country Status (11)

Country Link
US (2) US5427940A (el)
EP (2) EP0590034B1 (el)
JP (2) JPH06508688A (el)
AT (1) ATE145065T1 (el)
AU (2) AU656213B2 (el)
CA (2) CA2103142A1 (el)
DE (1) DE69215092T2 (el)
DK (1) DK0590034T3 (el)
ES (1) ES2096084T3 (el)
GR (1) GR3022302T3 (el)
WO (2) WO1992021979A1 (el)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427940A (en) * 1991-06-03 1995-06-27 Board Of Regents, The University Of Texas System Engineered cells producing insulin in response to glucose
US5744327A (en) * 1990-02-20 1998-04-28 Board Of Regents, The University Of Texas System Methods for producing insulin in response to non-glucose secretagogues
US5792656A (en) * 1991-06-03 1998-08-11 Board Of Regents, The University Of Texas System Methods of preparing genetically engineered cells that produce insulin in response to glucose
US6348327B1 (en) * 1991-12-06 2002-02-19 Genentech, Inc. Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
AU688304B2 (en) * 1993-02-09 1998-03-12 Monash University Methods for the diagnosis of diabetes and prediabetic conditions
US6008047A (en) * 1993-04-08 1999-12-28 Livercell L.L.C. Cell culturing method and medium
AU687386B2 (en) * 1993-04-08 1998-02-26 Human Cell Cultures, Inc. Cell culturing method and medium
EP0707646A1 (en) * 1993-06-28 1996-04-24 The Board Of Regents, The University Of Texas System Vectors for genetically engineered cells that produce insulin in response to glucose
US5547847A (en) * 1993-09-07 1996-08-20 University Of Washington Diagnosis of insulin-dependent diabetes
CA2188675A1 (en) * 1994-04-11 1995-10-19 Savio L. C. Woo Compositions and methods for gene therapy to treat disease
ES2156788B1 (es) * 1994-07-07 2002-02-01 Univ Barcelona Autonoma Genes quimericos que utilizan el cdna en orientacion antisentido del transportador de glucosa-2 (glut2) y animales transgenicos no humanos que expresan dichos genes quimericos para su utilizacion en el estudio de la diabetes mellitus y en el desarrollo de aproximaciones terapeuti
US5955579A (en) * 1995-05-09 1999-09-21 Strang Cancer Prevention Center Islet-specific homeoprotein and transcriptional regulator of insulin gene expression, HOXB13
US5891717A (en) * 1996-01-19 1999-04-06 Betagene, Inc. Methods and compositions for inhibiting hexokinase
US5854067A (en) * 1996-01-19 1998-12-29 Board Of Regents, The University Of Texas System Hexokinase inhibitors
US6087129A (en) 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US6352857B1 (en) 1997-01-21 2002-03-05 Wisconsin Alumni Research Foundation Treatment of diabetes with synthetic beta cells
WO1999035242A1 (en) * 1998-01-12 1999-07-15 Betagene, Inc. Media for neuroendocrine cells
WO1999054451A1 (en) * 1998-04-20 1999-10-28 Vanderbilt University Neuroendocrine cells secreting insulin ans uses thereof
US6537806B1 (en) * 1998-06-02 2003-03-25 University Of Washington Compositions and methods for treating diabetes
US6365385B1 (en) 1999-03-22 2002-04-02 Duke University Methods of culturing and encapsulating pancreatic islet cells
US6303355B1 (en) 1999-03-22 2001-10-16 Duke University Method of culturing, cryopreserving and encapsulating pancreatic islet cells
US6774120B1 (en) * 1999-06-01 2004-08-10 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
US8778899B2 (en) * 1999-06-01 2014-07-15 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
US6716824B1 (en) * 1999-10-22 2004-04-06 F. Charles Brunicardi Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy
JP2004530431A (ja) * 2001-06-08 2004-10-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 免疫隔離装置内の細胞株活性を改善する方法
US6642003B2 (en) 2001-08-02 2003-11-04 Cedars-Sinai Medical Center Human glucose-dependent insulin-secreting cell line
US7141240B2 (en) * 2002-03-12 2006-11-28 Cedars-Sinai Medical Center Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
US20050014692A1 (en) * 2003-01-21 2005-01-20 Newgard Christopher B. Lactate dehydrogenase as a novel target and reagent for diabetes therapy
WO2004065552A2 (en) * 2003-01-21 2004-08-05 Duke University Cell-based therapies for diabetes mellitus and other glucose intolerant states
WO2005020977A1 (en) * 2003-08-21 2005-03-10 Wisconsin Alumni Research Foundation Alpha-ketoglutarate potentiators of insulin secretion
EP1586650A1 (de) * 2004-04-16 2005-10-19 ProBioGen AG Eingriff in den Energiestoffwechsel von eukaryontenzellen zur Selektion und Expressionssteigerung
US20070128584A1 (en) * 2005-12-01 2007-06-07 Illani Atwater Method for isolation of cells
ES2550229T3 (es) 2007-08-10 2015-11-05 University Of Technology, Sydney Células modificadas genéticamente para comprender glucoquinasa de islote pancreático y usos de éstas
CA2836921C (en) 2011-06-07 2020-08-18 Wisconsin Alumni Research Foundation Hepatocyte based insulin gene therapy for diabetes
JP6650393B2 (ja) 2013-06-13 2020-02-19 オージェネシス リミテッド 細胞の集団、分化転換の方法及びその使用方法
MA41296A (fr) 2014-12-30 2017-11-07 Orgenesis Ltd Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
EP3635106A4 (en) 2017-05-08 2021-01-06 Orgenesis Ltd. POPULATIONS OF TRANSDIFFERENTIATED CELLS AND THEIR METHODS OF USE
US20210290821A1 (en) * 2018-07-27 2021-09-23 Washington University Cell-embedded vascular graft for transplantation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2757169A1 (de) * 1977-12-22 1979-07-05 Hoechst Ag Verfahren zur gewinnung insulin produzierender tierischer zellen
US4353888A (en) * 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
WO1987005929A1 (en) * 1986-04-01 1987-10-08 Genelabs Incorporated Immortalized cells which produce tissue-specific products
DE3752347T2 (de) * 1986-05-20 2002-09-26 The General Hospital Corp., Boston Verfahren zur pharmakokinetischen Studie der Insulin-Expression mit nicht-menschlichem Transgen-Säugetier
IL85203A0 (en) * 1988-01-26 1988-07-31 Yeda Res & Dev Assay for diabetes
EP0448635B1 (en) * 1988-12-13 1995-09-20 University Of Florida Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
NO306996B1 (no) * 1989-02-17 2000-01-24 Bayer Ag Isolert bukspyttkjerteloey-celle-(ICA)-antigen for in vitro- bruk
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
US5002661A (en) * 1989-08-25 1991-03-26 W. R. Grace & Co.-Conn. Artificial pancreatic perfusion device
GB8928884D0 (en) * 1989-12-21 1990-02-28 Feldmann Marc Transformed cell lines
US5175085A (en) * 1990-02-20 1992-12-29 Board Of Regents, The University Of Texas System Methods and compositions for diagnosing autoimmune insulin dependent diabetes mellitus
US5427940A (en) * 1991-06-03 1995-06-27 Board Of Regents, The University Of Texas System Engineered cells producing insulin in response to glucose
JP2649103B2 (ja) * 1990-08-17 1997-09-03 ユニバーシティー オブ フロリダ インシュリン依存性真性糖尿病の早期検出及び処置のための方法及び組成物
SG48813A1 (en) * 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
FR2710654B1 (fr) * 1993-09-30 1995-12-22 Maryam Asfari Nouvelles lignées de cellules sécrétrices d'insuline, leurs procédés d'obtention par voie de manipulation génétique et leur utilisation chez des sujets diabétiques sous forme protégée.

Also Published As

Publication number Publication date
JPH06508688A (ja) 1994-09-29
CA2103365A1 (en) 1992-12-04
WO1992021979A1 (en) 1992-12-10
US5427940A (en) 1995-06-27
ES2096084T3 (es) 1997-03-01
DE69215092T2 (de) 1997-05-22
WO1992021756A1 (en) 1992-12-10
EP0587771A1 (en) 1994-03-23
ATE145065T1 (de) 1996-11-15
EP0590034A1 (en) 1994-04-06
JPH06508266A (ja) 1994-09-22
AU2190792A (en) 1993-01-08
AU2191892A (en) 1993-01-08
AU656613B2 (en) 1995-02-09
US5747325A (en) 1998-05-05
AU656213B2 (en) 1995-01-27
EP0590034B1 (en) 1996-11-06
DE69215092D1 (de) 1996-12-12
CA2103142A1 (en) 1992-12-04
DK0590034T3 (da) 1996-11-25

Similar Documents

Publication Publication Date Title
GR3022302T3 (en) Method for determining the presence of diabetes associated antibodies or islet cell directed antibodies
WO2002101019A3 (en) Methods of culturing animal cells and polypeptide production in animal cells
DE60314602D1 (de) Verfahren zur isolierung und kulturexpansion mesenchymaler stamm-/vorläuferzellen aus nabelschnurblut sowie verfahren zur differenzierung von aus nabelschnurblut stammenden mesenchymalen stamm-/vorläuferzellen in unterschiedliche mesenchymgewebe
GB1567899A (en) Ev method of in vitro biosynthesis of hormones particularly insulin
Evans et al. Large-scale production of murine monoclonal antibodies using hollow fiber bioreactors
AU2659488A (en) Transfectant cell lines which express the major human rhinovirus receptor
Ebinger et al. Plasticity in growth behavior of patients’ acute myeloid leukemia stem cells growing in mice
Prentice et al. Improving performance of mammalian cells in fed‐batch processes through “bioreactor evolution”
EP4008774A1 (en) Cell culture method and application thereof based on high-density and continuous inoculation
Turner et al. Cybernetic modeling of bacteriol cultures at low growth rates: Single‐substrate systems
CN102776260A (zh) 一种高效表达重组人凝血八因子的方法
Bodnar et al. Characterization of human islet‐like structures generated from pancreatic precursor cells in culture
Vatandoost et al. A study of recombinant factor IX in Drosophila insect S2 cell lines through transient gene expression technology
Eberhard et al. Investigations of reactors for insect cell culture.
Golmakany et al. Continuous production of monoclonal antibody in a packed‐bed bioreactor
Righelato et al. Kinetics of ethanol production by yeast in continuous culture
Kuhn et al. High-density tissue-like cultivation of JAR choriocarcinoma cells for the in vitro production of human xylosyltransferase
Jäger A novel perfusion system for the large-scale cultivation of animal cells based on a continuous flow centrifuge
Bechler et al. Culture of hybridoma and Friend leukemia virus transformed cells in microgravity. Spacelab IML-1 mission
Yamaji et al. Continuous IgG production by myeloma cells immobilized within porous support particles
Werner et al. Fermentation with immobilized cell cultures.
AU581819B2 (en) Process for the immortalization of human and animal cells
Chen A perfusion system for high productivity of monoclonal antibody by hybridoma cells in a CelliGen bioreactor
JP3763865B2 (ja) 膵臓β細胞株と、バイオハイブリッド型人工膵島
Güven et al. Single cell protein production and reduction of pollutants in waste sulfite liquor